Arcturus Could Find Its COVID-19 Vaccine Limited To Smaller Markets
The company plans to seek an EUA in Vietnam for ARCT-154, but some analysts have questioned its prospects in major markets like the US.
You may also be interested in...
The two companies signed a development and commercialization deal with a $200m upfront payment and milestones of up to $4.3bn.
Shuttle Pharmaceuticals and PaxMedica launch two small initial public offerings in the US as the market awaits a significant IPO. Also, Assertio closed a $70m follow-on offering, Codiak restructures and cuts jobs, and Vilya emerges with $50m in series A venture capital.
Phase II/III data for mRNA-1273.211 showed superiority against variants of concern to the original Spikevax, but Moderna’s top competitor has questioned the need for multivalent approaches.